Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema

Ocular Immunology and Inflammation

Volumn 17, Issue 6, 2009, Pages 423-430

  Lasave, Andrés F ^a   Zeballos, David G ^a   El Haig, Wael M ^b   Daz Llopis, Manuel ^c   Salom, David ^c   Arevalo, J Fernando ^a  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

^b ZAGAZIG UNIVERSITY   (Egypt)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bevacizumab; Noninfectious uveitis; Single intravitreal injection; Triamcinolone acetonide; Uveitic cystoid macular edema

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA CYSTOID EDEMA; UVEITIS; VISUAL ACUITY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAOCULAR; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; UVEITIS; VISUAL ACUITY; VITREOUS BODY;

EID: 72449173819     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273940903221610     Document Type: Article

References (18)

1. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336.
2. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100:818-825.
3. Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004;111:946-953.
4. Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97:297-309.
5. Cunha-Vaz JG. The blood-retinal barriers system: basic concepts and clinical evaluation. Exp Eye Res. 2004;78:715-721.
6. Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351-361.
7. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades-Bechet's disease. Ann Intern Med. 2004;140:404-406.
8. de Vries J, Baarsma GS, Zaal MJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990;74:344-349.
9. Taylor SR, Habot-Wilner Z, Pacheco P, et al. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116:797-801.
10. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001; 108:765-772
11. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
12. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
13. Arevalo JF, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009 Jun 20. [Epub ahead of print]
14. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140:509-516
15. Angunawela RI, Heatley CJ, Williamson TH, et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: long-term management and outcome. Acta Ophthalmol Scand. 2005;83:595-599.
16. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574-1579.
17. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28:41-45.
18. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.